About the Company
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADGI News
Invivyd Announces CEO Transition
The Invivyd Board of Directors is positioning the company for its next phase of growth,” said Marc Elia, Chairperson. “Invivyd is poised to lead a brand-new paradigm in delivering novel, impactful ...
Invivyd Inc Ordinary Shares IVVD
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
FDA Gives Emergency Use Nod To Invivyd's Antibody To Prevent COVID-19 Infection In Adults, Adolescents With Weak Immune System
Friday, the FDA granted emergency use authorization to Invivyd Inc’s (NASDAQ:IVVD) Pemgarda (pemivibart), formerly VYD222, a half-life extended monoclonal antibody (mAb) for the pre-exposure ...
Invivyd Appoints Jeremy Gowler As Interim CEO As Dave Hering Resigns
Invivyd, Inc. (IVVD), a biopharmaceutical company, Friday said in a statement that it appointed Jeremy Gowler as Interim Chief ...
Invivyd, Inc. (IVVD) Interactive Stock Chart - Yahoo Finance
Jeremy Gowler appointed Interim CEOWALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious ...
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases ...
Invivyd Inc (IVVD) Shares Plummet Below 1-Year High
Based on Invivyd Inc (IVVD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -79.98. The debt to equity ratio resting at ...
Invivyd's new COVID-19 PrEP therapy now available in U.S.
WALTHAM, Mass. - Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company, has announced the availability of its new product PEMGARDA™ for pre-exposure prophylaxis (PrEP) of COVID-19 in the U.S ...
Invivyd Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...